Policosanol Nanoparticles for Lipid Control

Solution Overview

Problem

Policosanol formulations have shown inconsistent results in modulating serum lipid and cholesterol levels, with numerous studies outside Cuba failing to verify the initial claims of lipid-lowering effects, and have no significant impact on other metabolic and physiologic parameters.

Innovation Solution

Development of nanoparticulate policosanol formulations with an effective average particle size of less than 100 nm, incorporating a policosanol fraction predominantly composed of octacosanol and a stabilizer fraction including tocopheryl polyethylene glycol succinate (TPGS), which are administered to lower cholesterol and serum lipids, reduce blood pressure, exert antioxidant effects, mitigate insulin resistance, and regulate blood sugar levels.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If policosanol is administered in conventional formulations, then it shows lipid-lowering effects in Cuban studies, but these effects cannot be verified in independent studies outside Cuba

Engineering Contradiction:
Core Design Contradiction:
ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent transforms policosanol from conventional bulk form into nanoparticulate form with controlled size parameters (20-100 nm), changing the physical state and surface area to volume ratio, which improves bioavailability and metabolic interaction, thereby achieving consistent lipid-lowering effects across different study conditions

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The invention creates a composite nanoparticulate system combining policosanol with stabilizers and surfactants (such as tocopherol polyethylene glycol succinate), forming a heterogeneous structure that enhances solubility, stability, and cellular uptake, resolving the inconsistency observed in pure policosanol formulations

Inventive Principle:
Principle #40Composite materials

2Reliability

If policosanol particle size is reduced to nanoparticulate form, then bioavailability and metabolic interaction are improved, but manufacturing complexity increases

Engineering Contradiction:
Core Design Contradiction:
ReliabilityVSDevice complexity

Solution Approach 1:

The nanoparticulate policosanol formulation utilizes self-assembly properties where policosanol molecules spontaneously organize into nanoparticles in the presence of stabilizers, eliminating the need for complex top-down nanoparticle fabrication equipment and processes while achieving consistent nano-size distribution

Inventive Principle:
Principle #25Self-service

Solution Approach 2:

The patent introduces stabilizers and surfactants as intermediary substances that mediate between policosanol and the aqueous environment, facilitating nanoparticle formation and stabilization without requiring complex manufacturing controls, thereby simplifying the overall production process

Inventive Principle:
Principle #24Intermediary (Mediator)

Data Source

PatentEP2398476B1Policosanol nanoparticles
Publication Date: 2018.02.07
  • EP2398476B1 patent drawingFigure 1
  • EP2398476B1 patent drawingFigure 2
  • EP2398476B1 patent drawingFigure 3

AI summary

The present invention provides nanoparticulate policosanol, formulations including these particles, as a well as methods of using the particles and formulations for treatment and prophylaxis of various diseases and conditions.